Skip to content
DataLookout
Menu

NCT07933848

A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment

StatusNot Yet Recruiting
PhasePhase 1
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prifetrastat
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Prifetrastat
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose

Secondary (5)

Number of Treatment-Emergent Adverse Events (AE) by Severity
Number of Participants With Clinically Significant Clinical Laboratories Abnormalities
Number of Participants With Clinically Significant Change From Baseline in Blood Pressure or Heart Rate
Number of Participants With Abnormalities in Physical Examination
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings

Arms and interventions

Moderate Renal Impairment (Cohort 1)Experimental

Prifetrastat administered by mouth as a single dose in participants with moderate renal impairment (eGFR = 30-59 mL/min).

Severe Renal Impairment (Cohort 2)Experimental

Prifetrastat administered by mouth as a single dose in participants with severe renal impairment (eGFR \< 30 mL/min).

Normal Renal Function (Cohort 3)Active comparator

Prifetrastat administered by mouth as a single dose in participants with normal renal function (eGFR ≥ 90 mL/min).

Drugs: Prifetrastat

Sites

3 sites in 1 country